Metreleptin A Potential Therapy to Improve Blood Glucose Levels in Type 1 Diabetics
Metreleptin is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy homeostasis, fat and glucose metabolism and body weight.
JDRF & Amylin Pharmaceuticals, Inc. Team Up
The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. have teamed up to join a research collaboration to provide financial support for a clinical study to see if the effects of metreleptin could become a new treatment for type 1 diabetes.
“This proof-of-concept clinical study will investigate whether treatment with metreleptin can help improve blood sugar control and decrease the daily doses of insulin required in patients with type 1 diabetes. This is the first clinical study evaluating metreleptin treatment in patients with type 1 diabetes. The study will also evaluate whether treatment with metreleptin can improve variability in blood sugar levels, including the propensity for hypoglycemia (low blood sugar levels), which affects many people with type 1 diabetes.”
If the use of metreleptin has the same outcome as the lad studies did with mice then "Achieving a substantial reduction in insulin doses and lowering the risk of low blood glucose levels could enhance the quality of life for people with type 1 diabetes.” Said Dr. Unger
Source: Juvenile Diabetes Research Foundation